Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37834095)

  • 21. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
    Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
    Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
    Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
    Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
    Robak P; Robak T
    Drugs R D; 2019 Jun; 19(2):73-92. PubMed ID: 30993606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
    Elbæk CR; Petrosius V; Sørensen CS
    Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.
    Ba D; Li H; Liu R; Zhang P; Tang Y
    Apoptosis; 2023 Dec; 28(11-12):1534-1545. PubMed ID: 37243774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
    Summers RJ; Teachey DT
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
    Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
    Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe.
    Martin JC; Sims JR; Gupta A; Bakin AV; Ohm JE
    Cancer Res Commun; 2022 Jun; 2(6):471-482. PubMed ID: 36338546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
    Yue Y; Wang Y; He Y; Yang S; Chen Z; Wang Y; Xing S; Shen C; Amin HM; Wu D; Song YH
    PLoS One; 2014; 9(3):e90992. PubMed ID: 24608798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
    Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of bortezomib in the treatment of acute lymphoblastic leukemia.
    Zahid MF
    Future Oncol; 2016 Aug; 12(16):1861-4. PubMed ID: 27173950
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
    Citrin R; Foster JB; Teachey DT
    Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.